Genetic Disorders

FDA grants orphan drug status to Ionis’ olezarsen for FCS treatment

The US Food and Drug Administration (FDA) has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen, an investigational ligand conjugated…

Kyowa Kirin acquires Orchard Therapeutics for $477.6m

Kyowa Kirin, a Japan-based global speciality pharmaceutical company, has announced the successful completion of its acquisition of Orchard Therapeutics, a…

Palvella and Ligand partner for Phase III rare lymphatic tumour trial

Palvella Therapeutics has partnered with Ligand Pharmaceuticals for the Phase III clinical trial investigating topical Qtorin rapamycin for the treatment…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close